Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. (March 2012)

• Record Type: Journal Article
• Authors: Yan, Li; Shu-Ying, Yang; Shan, Kang; Yip, Benjamin HK; Rong-Miao, Zhou; Na, Wang; Hai-Yan, Sun
• Is Part Of: Pharmacogenomics. Volume 13:Number 4(2012)
• Page Start: 419
• Page End: 427
• Publication Date: 2012-03
• Subjects: 19007T/C SNP -- 8092C/A SNP -- epithelial ovarian cancer -- ERCC1 -- platinum chemotherapy -- SNP; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.11.181
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: We evaluated whether the ERCC1 polymorphisms had an effect on survival in epithelial ovarian cancer (EOC) patients with platinum-based chemotherapy.Materials & methods : Clinical data of 209 EOC patients between 2002 and 2008 were reviewed. The genotypes of 19007T/C and 8092C/A polymorphisms were assessed in all patients using PCR–RFLP.Results: The 19007T/C polymorphism was significantly associated with response to treatment. Compared with the patients carrying C/C genotype, the patients with the T/T genotype have a significantly decreased response to platinum-based chemotherapy (odds ratio: 32.26; 95% CI: 3.66–250.00). Cox''s multivariate analysis suggested that EOC patients with the T/T genotype had an increased risk of disease progression (hazard ratio: 3.34; 95% CI: 1.77–6.29) and death (hazard ratio: 2.87; 95% CI: 1.38–5.96) compared with those carrying the C/C genotype.Conclusion: The 19007T/C polymorphism may be a useful prognostic marker in patients with EOC treated with platinum-based chemotherapy in Chinese women. Original submitted 26 October 2011; Revision submitted 5 December 2011